Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

GlobeNewswire October 30, 2024

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

GlobeNewswire September 29, 2024

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

GlobeNewswire August 28, 2024

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire August 27, 2024

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

GlobeNewswire July 30, 2024

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

GlobeNewswire July 23, 2024

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

GlobeNewswire July 21, 2024

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

GlobeNewswire July 8, 2024

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

GlobeNewswire July 1, 2024

Mesoblast Corporate Presentation at Investor Conference

GlobeNewswire June 2, 2024

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

GlobeNewswire April 29, 2024

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

GlobeNewswire March 25, 2024

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

GlobeNewswire March 13, 2024

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

GlobeNewswire March 10, 2024

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

GlobeNewswire February 28, 2024

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire February 26, 2024

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

GlobeNewswire February 14, 2024

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

GlobeNewswire January 30, 2024

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

GlobeNewswire January 18, 2024

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

GlobeNewswire November 26, 2023